These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Sirolimus-eluting stent thrombosis several years after clopidogrel discontinuation. Joyal D; Rudski L J Invasive Cardiol; 2007 Sep; 19(9):E265-7. PubMed ID: 17827517 [TBL] [Abstract][Full Text] [Related]
9. [Should we use clopidogrel instead of ticlopidine in elective coronary angioplasty?]. Baralis G; Steffenino G; Dellavalle A; La Scala E; Uslenghi E Ital Heart J Suppl; 2003 Sep; 4(9):766-70. PubMed ID: 14635395 [TBL] [Abstract][Full Text] [Related]
10. Coronary artery disease: Platelet activity: an obstacle for successful PCI. Gawaz M; Geisler T Nat Rev Cardiol; 2009 Jun; 6(6):391-2. PubMed ID: 19471282 [TBL] [Abstract][Full Text] [Related]
11. The excel stent: a good DES, but can we really stop clopidogrel after 6 months? Margolis JR JACC Cardiovasc Interv; 2009 Apr; 2(4):310-1. PubMed ID: 19463442 [No Abstract] [Full Text] [Related]
12. Very late paclitaxel-eluting stent thrombosis despite 21 months of clopidogrel treatment after percutaneous coronary intervention. Sardella G; Bucciarelli-Ducci C; Mancone M; Colantonio R; Sangiorgi GM; Fedele F J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):625-8. PubMed ID: 17667035 [TBL] [Abstract][Full Text] [Related]
14. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials. Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW; JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715 [TBL] [Abstract][Full Text] [Related]
15. Confined late stent thrombosis following clopidogrel withdrawal in a patient with multi-segment sirolimus-eluting stent implants. Zavalloni D; Belli G; Rossi M; Presbitero P J Cardiovasc Med (Hagerstown); 2007 Jul; 8(7):544-6. PubMed ID: 17568291 [No Abstract] [Full Text] [Related]
16. Clopidogrel use in diabetic patients with new stents. Cardiovasc J Afr; 2008; 19(4):232. PubMed ID: 18776976 [No Abstract] [Full Text] [Related]
17. Long-term outcomes in treating left main trifurcation coronary artery disease with the Paclitaxel-eluting stent. Shammas NW; Dippel EJ; Avila A; Gehbauer L; Farland L; Brosius S; Jerin M; Winter M; Stoakes P; Byrd J; Majetic L; Shammas G; Sharis P; Robken J J Invasive Cardiol; 2007 Feb; 19(2):77-82. PubMed ID: 17268042 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. Han Y; Jing Q; Xu B; Yang L; Liu H; Shang X; Jiang T; Li Z; Zhang H; Li H; Qiu J; Liu Y; Li Y; Chen X; Gao R; JACC Cardiovasc Interv; 2009 Apr; 2(4):303-9. PubMed ID: 19463441 [TBL] [Abstract][Full Text] [Related]
19. Intraoperative thrombosis of right coronary artery drug-eluting stent after 2 years of dual antiplatelet therapy. Murray AT; Sederberg JH Semin Cardiothorac Vasc Anesth; 2011; 15(1-2):40-3. PubMed ID: 21840879 [TBL] [Abstract][Full Text] [Related]
20. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM; Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]